Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Banner Heart Hospital
mi
from
Mesa, AZ
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Banner Heart Hospital
mi
from
Mesa, AZ
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Banner Good Samaritan
mi
from
Phoenix, AZ
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Banner Good Samaritan
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Torrance Memorial Medical Center
mi
from
Torrance, CA
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Torrance Memorial Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Medical Center
mi
from
Elk Grove Village, IL
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Medical Center
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Boone Hospital Center
mi
from
Columbia, MO
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Boone Hospital Center
mi
from
Columbia, MO
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Presbyterian Health System Hospital
mi
from
Albuquerque, NM
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Presbyterian Health System Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Peace Health Sacred Heart River Bend Medical Center
mi
from
Springfield, OR
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Peace Health Sacred Heart River Bend Medical Center
mi
from
Springfield, OR
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
York Hospital
mi
from
York, PA
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
York Hospital
mi
from
York, PA
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Pilot Study of Dietary Chloride Supplementation on Cardiorenal Function in Heart Failure
Prospective "Pre-post" Pilot Study on the Effects of Dietary Chloride Supplementation on Neurohormonal and Diuretic Function in Patients With Heart Failure
Status: Enrolling
Updated:  12/31/1969
Yale-New Haven Hospital
mi
from
New Haven, CT
A Pilot Study of Dietary Chloride Supplementation on Cardiorenal Function in Heart Failure
Prospective "Pre-post" Pilot Study on the Effects of Dietary Chloride Supplementation on Neurohormonal and Diuretic Function in Patients With Heart Failure
Status: Enrolling
Updated: 12/31/1969
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Cardiac Vascular Reconstruction DynaCT for TAVI Procedures
Cardiac Vascular Reconstruction (CAVAREC) DynaCT for 3D Assessment of Aortic Valve During TAVI Procedures
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Cardiac Vascular Reconstruction DynaCT for TAVI Procedures
Cardiac Vascular Reconstruction (CAVAREC) DynaCT for 3D Assessment of Aortic Valve During TAVI Procedures
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10757 - Cardiology, P.C.
mi
from
Birmingham, AL
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10757 - Cardiology, P.C.
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital
mi
from
Birmingham, AL
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center
mi
from
Gilbert, AZ
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10786 - Cardiovascular Associates of Mesa
mi
from
Mesa, AZ
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10786 - Cardiovascular Associates of Mesa
mi
from
Mesa, AZ
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10756 - Mayo Clinic
mi
from
Phoenix, AZ
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10756 - Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13023 - University of Arizona Medical Center
mi
from
Tucson, AZ
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13023 - University of Arizona Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10754 - University of California, San Diego
mi
from
La Jolla, CA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10754 - University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10759 - Scripps Clinic
mi
from
La Jolla, CA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10759 - Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13265 - University of California, Los Angeles
mi
from
Los Angeles, CA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13265 - University of California, Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10775 - Cedars-Sinai Medical Care Foundation
mi
from
Los Angeles, CA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10775 - Cedars-Sinai Medical Care Foundation
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10778 - Orange County Cardiology
mi
from
Orange, CA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10778 - Orange County Cardiology
mi
from
Orange, CA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13031 - St. John's Regional Medical Center
mi
from
Oxnard, CA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13031 - St. John's Regional Medical Center
mi
from
Oxnard, CA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13275 - Stanford University Hospital
mi
from
Stanford, CA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13275 - Stanford University Hospital
mi
from
Stanford, CA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13267 - Bethesda Heart Hospital
mi
from
Boynton Beach, FL
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13267 - Bethesda Heart Hospital
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10780 - Morton Plant Hospital
mi
from
Clearwater, FL
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10780 - Morton Plant Hospital
mi
from
Clearwater, FL
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10760 - Shands Hospital, University of Florida
mi
from
Gainesville, FL
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10760 - Shands Hospital, University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13273 - University of Florida Health
mi
from
Jacksonville, FL
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13273 - University of Florida Health
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10768 - University of Miami
mi
from
Miami, FL
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10768 - University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13280
mi
from
Orlando, FL
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13280
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13264 - Florida Hospital Pepin Heart Institute
mi
from
Tampa, FL
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13264 - Florida Hospital Pepin Heart Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13027 - Emory University School of Medicine
mi
from
Atlanta, GA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13027 - Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10765 - Georgia Regents University
mi
from
Augusta, GA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10765 - Georgia Regents University
mi
from
Augusta, GA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10772 - University Cardiologist, Rush University Medical Center
mi
from
Chicago, IL
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10772 - University Cardiologist, Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13030 - University of Iowa
mi
from
Iowa City, IA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13030 - University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10783 - Gill Heart Institute, University of Kentucky
mi
from
Lexington, KY
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10783 - Gill Heart Institute, University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13022 - University of Louisville
mi
from
Louisville, KY
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13022 - University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13266
mi
from
New Orleans, LA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13266
mi
from
New Orleans, LA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10782
mi
from
Boston, MA
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10782
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10766 - Michigan Cardiovascular Institute
mi
from
Saginaw, MI
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10766 - Michigan Cardiovascular Institute
mi
from
Saginaw, MI
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10762 - Minneapolis Heart Institute
mi
from
Minneapolis, MN
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10762 - Minneapolis Heart Institute
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10761 - Mayo Clinic
mi
from
Rochester, MN
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10761 - Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13281
mi
from
Las Vegas, NV
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13281
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13263 - RWJ Barnabas Heart Center
mi
from
Newark, NJ
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13263 - RWJ Barnabas Heart Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10776 - Columbia University Medical Center
mi
from
New York, NY
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10776 - Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 13026 - Sanger Heart and Vascular Institute, Carolinas Healthcare System
mi
from
Charlotte, NC
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 13026 - Sanger Heart and Vascular Institute, Carolinas Healthcare System
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10781 - Duke University
mi
from
Durham, NC
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10781 - Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated:  12/31/1969
Mesoblast Investigational Site 10758 - The Christ Hospital
mi
from
Cincinnati, OH
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Status: Enrolling
Updated: 12/31/1969
Mesoblast Investigational Site 10758 - The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials